Non-alcoholic fatty liver disease (NAFLD) and risk of hospitalization for Covid-19.
Carolyn T BramanteChristopher J TignanelliNirjhar DuttaEmma JonesLeonardo TamarizJeanne M ClarkMichael UsherGenevieve Metlon-MeauxSayeed IkramuddinPublished in: medRxiv : the preprint server for health sciences (2020)
NAFLD/NASH is a significant risk factor for hospitalization for Covid-19, and appears to account for risk attributed to obesity. Treatments for metabolic disease mitigated risks from NAFLD/NASH. More research is needed to confirm risk associated with visceral adiposity, and patients should be screened for and informed of treatments for metabolic syndrome.
Keyphrases
- metabolic syndrome
- insulin resistance
- coronavirus disease
- sars cov
- end stage renal disease
- ejection fraction
- newly diagnosed
- weight gain
- type diabetes
- chronic kidney disease
- adipose tissue
- prognostic factors
- peritoneal dialysis
- weight loss
- skeletal muscle
- cardiovascular disease
- high fat diet induced
- uric acid
- patient reported outcomes
- human health
- cardiovascular risk factors
- physical activity
- climate change
- risk assessment
- breast cancer risk